
Azenta (AZTA) Stock Forecast & Price Target
Azenta (AZTA) Analyst Ratings
Bulls say
Azenta Inc. reported an impressive adjusted gross margin of 47.5%, reflecting a year-over-year increase of 130 basis points, attributed to a favorable product mix, operational efficiencies, and revenue growth. The company's adjusted EBITDA margin also demonstrated significant improvement, rising 400 basis points year-over-year to 10.0%, surpassing analyst expectations. With strong revenue growth potential projected from its Multiomics and Sample Management Solutions segments, Azenta is poised for enhanced profitability and faster margin improvements.
Bears say
The financial outlook for Azenta Inc is viewed negatively due to anticipated lower revenue growth, driven primarily by heightened competition in the Multiomics sector and slower traction within the Sample Management Solutions segment. Additionally, declines in automated and cryogenic stores highlight a decreasing demand, particularly in the cell and gene therapy market, which may further impact overall profitability. These factors contribute to concerns regarding margin contraction and the potential for slowing or negative earnings per share growth.
This aggregate rating is based on analysts' research of Azenta and is not a guaranteed prediction by Public.com or investment advice.
Azenta (AZTA) Analyst Forecast & Price Prediction
Start investing in Azenta (AZTA)
Order type
Buy in
Order amount
Est. shares
0 shares